Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.168, issue.8, pp.918-51, 2003. ,
DOI : 10.1164/rccm.200304-505SO
Pseudomonas aeruginosa Biofilms, Adv Appl Microbiol, vol.86, pp.1-40, 2014. ,
DOI : 10.1016/B978-0-12-800262-9.00001-9
Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective, Nature Reviews Microbiology, vol.176, issue.12, pp.841-51, 2012. ,
DOI : 10.1038/nrmicro2907
infections, FEMS Microbiology Letters, vol.290, issue.1, pp.1-9, 2009. ,
DOI : 10.1111/j.1574-6968.2008.01394.x
Dampening Host Sensing and Avoiding Recognition in Pseudomonas aeruginosa Pneumonia, J Biomed Biotechnol, p.852513, 2011. ,
DOI : 10.1155/2011/852513
URL : https://hal.archives-ouvertes.fr/pasteur-00975374
Pseudomonas aeruginosa: all roads lead to resistance, Trends in Microbiology, vol.19, issue.8, pp.419-445, 2011. ,
DOI : 10.1016/j.tim.2011.04.005
Pseudomonas aeruginosa ? a phenomenon of bacterial resistance, Journal of Medical Microbiology, vol.58, issue.9, pp.1133-1181, 2009. ,
DOI : 10.1099/jmm.0.009142-0
biofilms in cystic fibrosis, Future Microbiology, vol.5, issue.11, pp.1663-74, 2010. ,
DOI : 10.2217/fmb.10.125
Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis, Cochrane Database Syst Rev, vol.8, p.1399, 2015. ,
infection, Human Vaccines & Immunotherapeutics, vol.67, issue.1, pp.14-20, 2015. ,
DOI : 10.1128/IAI.74.2.968-974.2006
Vaccines for Pseudomonas aeruginosa, Expert Rev Vaccines, vol.13, pp.507-526, 2014. ,
DOI : 10.1007/978-1-4615-0053-7_17
Vaccines for the 21st century, EMBO Molecular Medicine, vol.6, pp.708-728, 2014. ,
DOI : 10.1002/emmm.201403876
?, Future Microbiology, vol.7, issue.12, pp.1333-1338, 2012. ,
DOI : 10.2217/fmb.12.106
Recent developments for Pseudomonas vaccines, Human Vaccines, vol.3, issue.10, pp.999-1011, 2011. ,
DOI : 10.1016/j.virol.2008.04.016
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360073
Vaccines and immunotherapy against Pseudomonas aeruginosa, Vaccine, vol.26, issue.8, pp.1011-1035, 2008. ,
DOI : 10.1016/j.vaccine.2007.12.007
Promises and pitfalls of Pseudomonas aeruginosa lipopolysaccharide as a vaccine antigen, Carbohydrate Research, vol.338, issue.23, pp.2549-56, 2003. ,
DOI : 10.1016/S0008-6215(03)00312-4
Live-Attenuated Bacterial Vectors: Tools for Vaccine and Therapeutic Agent Delivery, Vaccines, vol.58, issue.4, pp.940-72, 2015. ,
DOI : 10.1016/S0168-3659(01)00340-6
URL : http://doi.org/10.3390/vaccines3040940
Live attenuated vaccines against pertussis, Expert Review of Vaccines, vol.13, issue.9, pp.1147-58, 2014. ,
DOI : 10.1586/14760584.2014.942222
Protection against Fatal Pseudomonas aeruginosa Pneumonia in Mice after Nasal Immunization with a Live, Attenuated aroA Deletion Mutant, Infection and Immunity, vol.71, issue.3, pp.1453-61, 2003. ,
DOI : 10.1128/IAI.71.3.1453-1461.2003
Pneumonia, American Journal of Respiratory and Critical Care Medicine, vol.186, issue.5, pp.420-427, 2012. ,
DOI : 10.1164/rccm.201202-0182OC
Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity, Nature Medicine, vol.166, issue.8, pp.853-60, 2005. ,
DOI : 10.1046/j.1365-2958.2002.03072.x
DNA Repair Enzymes, Annual Review of Biochemistry, vol.57, issue.1, pp.29-67, 1988. ,
DOI : 10.1146/annurev.bi.57.070188.000333
Fundamentals of the psoralen-based Helinx? technology for inactivation of infectious pathogens and leukocytes in platelets and plasma, Seminars in Hematology, vol.38, pp.4-11, 2001. ,
DOI : 10.1016/S0037-1963(01)90118-0
Killed but metabolically active vaccines. Current opinion in biotechnology, 2012. ,
DOI : 10.1016/j.copbio.2012.04.005
Killed but Metabolically Active Bacillus anthracis Vaccines Induce Broad and Protective Immunity against Anthrax, Infection and Immunity, vol.77, issue.4, pp.1649-63, 2009. ,
DOI : 10.1128/IAI.00530-08
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663168
A Safe Bacterial Microsyringe for In Vivo Antigen Delivery and Immunotherapy, Molecular Therapy, vol.21, issue.5, pp.1076-86, 2013. ,
DOI : 10.1038/mt.2013.41
URL : https://hal.archives-ouvertes.fr/hal-00813378
Bacterial vectors for active immunotherapy reach clinical and industrial stages, Human Vaccines & Immunotherapeutics, vol.55, issue.10, pp.1454-1462, 2012. ,
DOI : 10.1038/nrc2934
URL : https://hal.archives-ouvertes.fr/hal-00813376
Poly-functional and long-lasting anticancer immune response elicited by a safe attenuated Pseudomonas aeruginosa vector for antigens delivery, Molecular Therapy - Oncolytics, vol.3, p.16033, 2016. ,
DOI : 10.1038/mto.2016.33
URL : https://hal.archives-ouvertes.fr/hal-01463683
Anti-tumor Immunotherapy via Antigen Delivery from a Live Attenuated Genetically Engineered Pseudomonas aeruginosa Type III Secretion System-Based Vector, Molecular Therapy, vol.14, issue.5, pp.656-61, 2006. ,
DOI : 10.1016/j.ymthe.2006.06.011
URL : https://hal.archives-ouvertes.fr/inserm-00144349
Combined sacB-based negative selection and cre-lox antibiotic marker recycling for efficient gene deletion in Pseudomonas aeruginosa, BioTechniques, vol.38, issue.1, pp.63-70, 2005. ,
DOI : 10.2144/05381ST01
URL : https://hal.archives-ouvertes.fr/hal-00399228
H/HeN mice, APMIS, vol.254, issue.7-12, pp.838-880, 1997. ,
DOI : 10.1111/j.1699-0463.1997.tb05092.x
In vitro and in vivo T cell responses in mice during bronchopulmonary infection with mucoid Pseudomonas aeruginosa, Clinical & Experimental Immunology, vol.93, issue.Suppl., pp.98-105, 1995. ,
DOI : 10.1111/j.1365-2249.1995.tb03478.x
Chapter 11 Production of Recombinant Proteoliposomes for Therapeutic Uses, Methods Enzymol, vol.465, pp.209-232, 2009. ,
DOI : 10.1016/S0076-6879(09)65011-4
Coding of facial expressions of pain in the laboratory mouse, Nature Methods, vol.57, issue.6, pp.447-456, 2010. ,
DOI : 10.1016/j.neuron.2009.02.015
The type III secretion system of Pseudomonas aeruginosa: infection by injection, Nature Reviews Microbiology, vol.67, issue.9, pp.654-65, 2009. ,
DOI : 10.1038/nrmicro2199
In the Absence of Effector Proteins, the Pseudomonas aeruginosa Type Three Secretion System Needle Tip Complex Contributes to Lung Injury and Systemic Inflammatory Responses, PLoS ONE, vol.5, issue.11, p.81792, 2013. ,
DOI : 10.1371/journal.pone.0081792.s005
airway infection, Pediatric Pulmonology, vol.29, issue.7, pp.650-658, 2014. ,
DOI : 10.1002/ppul.22890
Full virulence of Pseudomonas aeruginosa requires OprF, Infect Immun, vol.79, pp.1176-86, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00858403
Outer Membrane Proteins of Pseudomonas aeruginosa Serotype Strains, Journal of Infectious Diseases, vol.146, issue.6, pp.770-779, 1982. ,
DOI : 10.1093/infdis/146.6.770
infection in mice, FEMS Immunology & Medical Microbiology, vol.61, issue.2, pp.179-88, 2011. ,
DOI : 10.1111/j.1574-695X.2010.00764.x
Available from: http://www.vaincrelamuco.org/sites/default/files/registre_francais_de_la_mucoviscido se_-_bilan_2015_v4.pdf 2 New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls. Pharmacol Ther, pp.19-34, 2015. ,
The lower airway microbiota in early cystic fibrosis lung disease: a longitudinal analysis, Cystic Fibrosis: Microbiology and Host Response, 2009. ,
DOI : 10.1136/thoraxjnl-2016-209279
Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.168, issue.8, pp.918-51, 2003. ,
DOI : 10.1164/rccm.200304-505SO
Pseudomonas aeruginosa Biofilms, Adv Appl Microbiol, vol.86, pp.1-40, 2014. ,
DOI : 10.1016/B978-0-12-800262-9.00001-9
Dampening Host Sensing and Avoiding Recognition in Pseudomonas aeruginosa Pneumonia, J Biomed Biotechnol, pp.852513-852522, 2011. ,
URL : https://hal.archives-ouvertes.fr/pasteur-00975374
Pseudomonas aeruginosa Evolutionary Adaptation and Diversification in Cystic Fibrosis Chronic Lung Infections, Trends in Microbiology, vol.24, issue.5, pp.327-364, 2016. ,
DOI : 10.1016/j.tim.2016.01.008
URL : http://doi.org/10.1016/j.tim.2016.01.008
Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev, 1996. ,
Resistance of mucoid Pseudomonas aeruginosa to nonopsonic phagocytosis by alveolar macrophages in vitro, Infect Immun, vol.56, issue.12, pp.3173-3182, 1988. ,
biofilms in cystic fibrosis, WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf [Internet], pp.1663-74, 2010. ,
DOI : 10.2217/fmb.10.125
Available from: http://www.who.int/medicines/publications/WHO-PPL- Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1 15 Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis, Cochrane Database Syst Rev, issue.8, pp.1399-1415, 2015. ,
Vaccines for Pseudomonas aeruginosa, Expert Rev Vaccines. 2014, vol.13, issue.4, pp.507-526 ,
DOI : 10.1007/978-1-4615-0053-7_17
40 years on: have we finally got a vaccine for Pseudomonas aeruginosa? Future Microbiol, pp.1333-1338, 2012. ,
DOI : 10.2217/fmb.12.106
Vaccines and immunotherapy against Pseudomonas aeruginosa, Vaccine, vol.26, issue.8, pp.1011-1035, 2008. ,
DOI : 10.1016/j.vaccine.2007.12.007
infection, Human Vaccines & Immunotherapeutics, vol.67, issue.1, pp.14-20, 2015. ,
DOI : 10.1128/IAI.74.2.968-974.2006
Vaccines for the 21st century Recent developments for Pseudomonas vaccines. Hum Vaccin, 22. Pier GB. Promises and pitfalls of Pseudomonas aeruginosa lipopolysaccharide as a vaccine antigen, pp.708-728, 2003. ,
Isolation and Characterization of Antigenic Components of a New Heptavalent Pseudomonas Vaccine, Nature New Biology, vol.229, issue.7, pp.209-219, 1971. ,
DOI : 10.1038/newbio229209a0
A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients, Proceedings of the National Academy of Sciences, vol.1, issue.8996, pp.11020-11025, 2006. ,
DOI : 10.1016/S0140-6736(96)90442-0
Recognition of Host Immune Activation by Pseudomonas aeruginosa, Science, vol.309, issue.5735, pp.774-781, 2005. ,
DOI : 10.1126/science.1112422
DNA vaccines against chronic lung infections by Pseudomonas aeruginosa, FEMS Immunol Med Microbiol Jul, vol.1537, pp.2-3147, 2003. ,
DOI : 10.1016/s0928-8244(03)00075-0
Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury, Nat Med, vol.5, issue.4, pp.392-400, 1999. ,
Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid, Journal of Clinical Investigation, vol.115, issue.5, pp.1281-1290, 2005. ,
DOI : 10.1172/JCI23135
Safety and Immunogenicity of an Oral Inactivated Whole-Cell Pseudomonas aeruginosa Vaccine Administered to Healthy Human Subjects, Infection and Immunity, vol.74, issue.2, 2006. ,
DOI : 10.1128/IAI.74.2.968-974.2006
Live-Attenuated Bacterial Vectors: Tools for Vaccine and Therapeutic Agent Delivery, Vaccines, vol.58, issue.4, pp.940-72, 2015. ,
DOI : 10.1016/S0168-3659(01)00340-6
URL : http://doi.org/10.3390/vaccines3040940
Live attenuated vaccines against pertussis, Expert Review of Vaccines, vol.13, issue.9, pp.1147-58, 2014. ,
DOI : 10.1586/14760584.2014.942222
Protection against Fatal Pseudomonas aeruginosa Pneumonia in Mice after Nasal Immunization with a Live, Attenuated aroA Deletion Mutant, Infection and Immunity, vol.71, issue.3, pp.1453-61, 2003. ,
DOI : 10.1128/IAI.71.3.1453-1461.2003
Pneumonia, American Journal of Respiratory and Critical Care Medicine, vol.186, issue.5, pp.420-427, 2012. ,
DOI : 10.1164/rccm.201202-0182OC
IL-17 Is a Critical Component of Vaccine-Induced Protection against Lung Infection by Lipopolysaccharide-Heterologous Strains of Pseudomonas aeruginosa, The Journal of Immunology, vol.181, issue.7, pp.4965-75, 1950. ,
DOI : 10.4049/jimmunol.181.7.4965
Fundamentals of the psoralen-based Helinx? technology for inactivation of infectious pathogens and leukocytes in platelets and plasma, Seminars in Hematology, vol.38, issue.4, pp.4-11, 2001. ,
DOI : 10.1016/S0037-1963(01)90118-0
Killed but metabolically active vaccines, Current Opinion in Biotechnology, vol.23, issue.6, pp.917-940 ,
DOI : 10.1016/j.copbio.2012.04.005
Killed but Metabolically Active Leishmania infantum as a Novel Whole-Cell Vaccine for Visceral Leishmaniasis, Clinical and Vaccine Immunology, vol.19, issue.4, pp.490-498 ,
DOI : 10.1128/CVI.05660-11
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3318268
Killed but Metabolically Active Bacillus anthracis Vaccines Induce Broad and Protective Immunity against Anthrax, Infection and Immunity, vol.77, issue.4, pp.1649-63, 2009. ,
DOI : 10.1128/IAI.00530-08
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663168
A Safe Bacterial Microsyringe for In Vivo Antigen Delivery and Immunotherapy, Molecular Therapy, vol.21, issue.5, pp.1076-86, 2013. ,
DOI : 10.1038/mt.2013.41
Bacterial vectors for active immunotherapy reach clinical and industrial stages. Hum Vaccines Immunother, pp.1454-1462, 2012. ,
Poly-functional and long-lasting anticancer immune response elicited by a safe attenuated Pseudomonas aeruginosa vector for antigens delivery, Molecular Therapy - Oncolytics, vol.3, p.16033, 2016. ,
DOI : 10.1038/mto.2016.33
URL : https://hal.archives-ouvertes.fr/hal-01463683